Rina-S: Clinical Trials

6 trials of Rina-S, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Recruiting 4, Active not recruiting 1, Not yet recruiting 1

Follow Rina-S: new trials by email Literature Review of Rina-S trials Research Report on Rina-S

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer
Phase 3Not yet recruitingGenmab6022026-11-012026-10-05
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
Phase 3RecruitingGenmab6882026-08-282026-11-04
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer
Phase 3RecruitingGenmab822026-06-262026-11-03
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Phase 3RecruitingGenmab5442026-04-032026-11-16
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Rina-S, IC - Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Phase 3RecruitingGenmab6602025-11-282026-11-03
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer
Phase 3Active not recruitingGenmab5842025-02-072026-11-03

Conditions studied

Ovarian Neoplasms (5)  ·  Fallopian Tube Neoplasms (3)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Endometrial Neoplasms (1)  ·  Recurrence (1)

Sponsors

Genmab (6)

Countries

Japan (4)  ·  United States (4)  ·  Australia (3)  ·  Belgium (3)  ·  Denmark (3)  ·  Finland (3)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Norway (3)  ·  Poland (3)  ·  Puerto Rico (3)  ·  Spain (3)  ·  Austria (2)  ·  Canada (2)

NIH funding

2025 (2)